NCT06362369 - A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Advanced CancerAdvanced Solid TumorMelanomaMetastasisPleural MesotheliomaRenal Cell CarcinomaMSI-HighMismatch Repair DeficiencyColorectal CancerHepatocellular CarcinomaHepatocellular CancerRenal Cell CancerKidney CancerSkin CancerNon Small Cell Lung CancerNSCLCAnaplastic Lymphoma Kinase Genomic Tumor AberrationsALK Genomic Tumor Aberrations

Interventions

DRUG

Alintegimod

Alintegimod will be provided in bottles of 30 softgel capsules for oral administration

DRUG

Ipilimumab

Ipilimumab (Yervoy) will be administered via IV

DRUG

Nivolumab

Nivolumab (Opdivo) will be administered via IV

Trial Locations (4)

32746

RECRUITING

Florida Cancer Specialists, Lake Mary

77030

RECRUITING

MD Anderson Cancer Center, Houston

03756

RECRUITING

Dartmouth Hitchcock, Lebanon

02906

RECRUITING

Brown University Health Cancer Institute, Providence